Evelo Biosciences. has filed a patent for a pharmaceutical composition containing bacteria or microbial extracellular vesicles and spirulina. The composition aims to provide novel methods for utilizing these components in solid dosage forms for potential therapeutic applications. GlobalData’s report on Evelo Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Evelo Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Evelo Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Evelo Biosciences's grant share as of January 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.

A pharmaceutical composition for preventing or treating diseases is disclosed in a filed patent (Publication Number: US20240024377A1). The composition includes a pharmaceutical agent comprising bacteria and/or microbial extracellular vesicles (mEVs) along with at least one component of spirulina. The spirulina component can be a nucleic acid, protein, or small molecule, such as spirulina DNA, phycocyanin protein, or chlorophyllin pigment. The bacteria in the composition are specified to be hemoglobin-dependent bacteria from various genera like Actinomyces, Prevotella, and Clostridium. The mEVs can be secreted or processed and are also derived from hemoglobin-dependent bacteria, including species like Prevotella histicola. The composition can be in the form of a solid dosage form, such as a tablet or capsule, with specific proportions of diluents, lubricants, glidants, and disintegration agents.

Furthermore, the patent also covers methods of using the pharmaceutical composition for disease prevention or treatment, as well as methods of preparing solid dosage forms containing bacteria, mEVs, and spirulina components. The methods involve combining the components, compressing them into a solid form, and potentially enterically coating the dosage form. Testing methods for detecting spirulina components in the composition are also disclosed, including assays for nucleic acids, proteins, and small molecules. Overall, the patent provides a detailed description of the pharmaceutical composition, solid dosage forms, methods of use, and testing procedures related to the innovative combination of bacteria, mEVs, and spirulina components for therapeutic purposes.

To know more about GlobalData’s detailed insights on Evelo Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies